Home » EMA Committee Recommends Full Approval of Imbruvica to Treat Two Blood Cancers
EMA Committee Recommends Full Approval of Imbruvica to Treat Two Blood Cancers
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending the granting of full marketing approval for Pharmacyclics' Imbruvica (ibrutinib) in the EU.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May